Literature DB >> 19489964

Allergic contact dermatitis from fragrance components in specific topical pharmaceutical products in Belgium.

Andrea Nardelli1, Ellen D'Hooghe, Jacques Drieghe, Marc Dooms, An Goossens.   

Abstract

OBJECTIVES: To determine which topical pharmaceutical products marketed in Belgium contain fragrances and to examine the nature of the fragrance allergens in specific pharmaceutical products having caused iatrogenic contact dermatitis.
METHODS: All topical pharmaceutical products marketed in Belgium, that is 3820 products, were examined as to their fragrance content as labelled. Data of 18, 960 patients investigated for contact allergy between 1978 and 2008 were retrieved from our database, including information on the nature of the topical pharmaceutical products used, the results of patch tests, and the sensitization sources.
RESULTS: Three hundred and seventy (10%) of 3280 of the topical pharmaceutical products were found to contain a total of 66 fragrance substances. Among 3378 patients suffering from iatrogenic allergic contact dermatitis, 127 were found to react to 48 specific products, for which 38 different fragrance substances gave relevant positive reactions. Women were more affected than men, and legs, hands, and face were the most commonly affected body sites.
CONCLUSIONS: Fragrances, the presence of which is in most cases unnecessary, do contribute to iatrogenic allergic contact dermatitis. Moreover, sensitized patients have difficulties in avoiding their specific allergens because standardized labelling of the ingredients in pharmaceutical products is lacking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19489964     DOI: 10.1111/j.1600-0536.2009.01542.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  3 in total

1.  Positive results of patch tests with fragrance markers: analysis of a 15-year period at a Brazilian dermatology center.

Authors:  Mariana de Figueiredo Silva Hafner; Sandy Daniele Germano Munhoz; Ariel Garcia Jeldes; Rosana Lazzarini
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

Review 2.  Position statement: The need for EU legislation to require disclosure and labelling of the composition of medical devices.

Authors:  A Herman; W Uter; T Rustemeyer; M Matura; K Aalto-Korte; J Duus Johansen; M Gonçalo; I R White; A Balato; A M Giménez Arnau; K Brockow; C G Mortz; V Mahler; A Goossens
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-05-06       Impact factor: 6.166

Review 3.  Ubiquity, Hazardous Effects, and Risk Assessment of Fragrances in Consumer Products.

Authors:  María-Antonia Pastor-Nieto; María-Elena Gatica-Ortega
Journal:  Curr Treat Options Allergy       Date:  2021-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.